SpringWorks Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• Nirogacestat oral tablet · Oncology
  Nirogacestat inhibits gamma-secretase, reducing the production of Notch intracellular domain and downstream signaling that drives abnormal cell proliferation in desmoid tumors.

Phase 1 pipeline

• Mirdametinib and Carbamazepine
• Nirogacestat and Famotidine
• Nirogacestat and Rabeprazole
• SW-682

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• SpringWorks Therapeutics, Inc. portfolio CI brief
• SpringWorks Therapeutics, Inc. pipeline updates RSS